<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19158" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cephalosporins</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bui</surname>
            <given-names>Toai</given-names>
          </name>
          <aff>SGMC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Preuss</surname>
            <given-names>Charles V.</given-names>
          </name>
          <aff>University of South Florida</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Toai Bui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Charles Preuss declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19158.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Cephalosporins are &#x003b2;-lactam antimicrobials used to manage various infections caused by both gram-positive and gram-negative bacteria. The&#x000a0;5 generations of cephalosporins demonstrate efficacy in treating skin and soft tissue infections, pneumonia, meningitis, and other infections. Cefiderocol is a novel siderophore cephalosporin that exhibits remarkable antibacterial activity. This drug has been approved by the US Food and Drug Administration (FDA) to treat complicated urinary tract infections and ventilator-associated pneumonia caused by highly resistant gram-negative bacteria, including <italic toggle="yes">Klebsiella pneumonia</italic>,&#x000a0;<italic toggle="yes">Proteus mirabilis</italic>, <italic toggle="yes">Escherichia coli</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, and <italic toggle="yes">Acinetobacter baumannii</italic>.</p>
        <p>Cefiderocol emerges as a promising therapeutic option for challenging infections, with literature reviews suggesting its potential in combating strains resistant to carbapenems. Importantly, cefiderocol&#x000a0;is the only recently approved&#x000a0;&#x003b2;-lactam agent exhibiting in vitro activity against carbapenem-resistant <italic toggle="yes">A baumannii</italic> (CRAB) isolates. According to the Infectious Diseases Society of America guidelines, cefiderocol should be reserved for cases of CRAB infections that remain unresponsive to other antibiotics or when intolerance to alternative agents prohibits their use. This activity provides&#x000a0;clinicians with comprehensive insights into indications,&#x000a0;mechanisms of action, contraindications, monitoring protocols, potential adverse drug reactions, and clinical toxicology associated with cephalosporins. This activity also provides healthcare professionals with essential knowledge and necessary tools to make informed decisions, promptly identify adverse effects, and optimize patient outcomes through vigilant monitoring and effective cephalosporin utilization, thereby ensuring proficiency in antibiotic therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the spectrum of activity of cephalosporins against both gram-positive and gram-negative bacteria.</p></list-item><list-item><p>Screen patients for potential contraindications and drug interactions before initiating cephalosporin therapy.</p></list-item><list-item><p>Implement appropriate dosing regimens and administration routes for cephalosporins based on the type and severity of infection.</p></list-item><list-item><p>Coordinate with other healthcare team members to ensure timely and appropriate use of cephalosporins in multidisciplinary patient care plans.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19158&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19158">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19158.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Cephalosporins are &#x003b2;-lactam antimicrobials used to manage various infections caused by both gram-positive and gram-negative bacteria. Cephalosporins are categorized into 5 generations based on their spectrum of coverage against gram-positive and gram-negative bacteria and their temporal discovery. The&#x000a0;5 generations of cephalosporins demonstrate efficacy in treating skin and soft tissue infections, pneumonia, meningitis, and other infections. First-generation cephalosporins have coverage against most gram-positive cocci and some gram-negative bacteria,&#x000a0;including&#x000a0;<italic toggle="yes">Escherichia coli, Proteus mirabilis, </italic>and<italic toggle="yes"> Klebsiella pneumoniae</italic>. Second-generation cephalosporins have coverage against <italic toggle="yes">Haemophilus influenzae, Moraxella catarrhalis, </italic>and <italic toggle="yes">Bacteroides</italic> spp<italic toggle="yes">. </italic>Third-generation cephalosporins have less coverage against most gram-positive organisms but have increased coverage against Enterobacteriaceae, <italic toggle="yes">Neisseria</italic> spp, and <italic toggle="yes">H influenzae</italic>. Fourth-generation cephalosporins have similar coverage as third-generation cephalosporins but with additional coverage against gram-negative bacteria&#x000a0;with antimicrobial resistance,&#x000a0;such as&#x000a0;&#x003b2;-lactamase. Fifth-generation cephalosporins have coverage against methicillin-resistant staphylococci and penicillin-resistant pneumococci.</p>
        <p>First-generation cephalosporins include cefazolin, cephalothin, cephapirin, cephradine, cefadroxil, and cephalexin. First-generation cephalosporins have active coverage against most gram-positive cocci, such as staphylococci spp<italic toggle="yes">&#x000a0;</italic>and streptococci spp<italic toggle="yes">,&#x000a0;</italic>while having minimal coverage against gram-negative bacteria. Gram-negative bacteria that are more susceptible to first-generation cephalosporins include&#x000a0;<italic toggle="yes">P mirabilis, E coli, </italic>and<italic toggle="yes"> K pneumoniae</italic>. Oral first-generation cephalosporins are commonly prescribed against uncomplicated skin and soft tissue infections such as cellulitis and abscesses due to staphylococci spp&#x000a0;or streptococci spp<italic toggle="yes">.</italic>&#x000a0;Additionally, clinicians can use them for bone, respiratory tract, genitourinary tract, biliary tract, bloodstream infection, otitis media, and surgical prophylaxis. Cefazolin is the cephalosporin of choice for surgical prophylaxis. One off-label use is first-generation cephalosporins for endocarditis prophylaxis for those susceptible and undergoing a dental or respiratory procedure.<xref ref-type="bibr" rid="article-19158.r1">[1]</xref><xref ref-type="bibr" rid="article-19158.r2">[2]</xref><xref ref-type="bibr" rid="article-19158.r3">[3]</xref></p>
        <p>Second-generation cephalosporins divide into&#x000a0;2 subgroups&#x02014;the second-generation and the cephamycin subgroup. Some of the second-generation subgroups include cefuroxime and cefprozil. The cephamycin subgroup includes cefmetazole, cefotetan, and cefoxitin. Within the first subgroup, cefuroxime has increased coverage against <italic toggle="yes">H influenzae</italic>. Indications for cefuroxime also include Lyme disease in pregnant women and children. The cephamycin subgroup has increased coverage against <italic toggle="yes">Bacteroides </italic>species. Second-generation cephalosporins have less activity against gram-positive cocci than first-generation cephalosporins but have improved activity against gram-negative bacilli. They are often prescribed to treat respiratory infections such as bronchiolitis or pneumonia. Other indications for second-generation cephalosporins are similar to first-generation indications (bone, respiratory tract, genitourinary tract, biliary tract, bloodstream infection, otitis media, and surgical prophylaxis). In addition to the gram-negative bacteria covered by first-generation cephalosporins, second-generation cephalosporins also have coverage against <italic toggle="yes">H&#x000a0;</italic><italic toggle="yes">influenzae, </italic><italic toggle="yes">E</italic><italic toggle="yes">nterobacter aerogenes, </italic><italic toggle="yes">N</italic><italic toggle="yes">eisseria </italic>spp<italic toggle="yes">, </italic>and <italic toggle="yes">S</italic><italic toggle="yes">erratia marcescens</italic>.<xref ref-type="bibr" rid="article-19158.r4">[4]</xref></p>
        <p>Third-generation cephalosporins include cefotaxime, ceftazidime, cefdinir, ceftriaxone, cefpodoxime, cefoperazone, and cefixime. This generation has extended gram-negative bacteria coverage, often used to treat gram-negative infections resistant to the first- and second-generation or other &#x003b2;-lactam antimicrobials. When given intravenously (IV), third-generation can penetrate the blood-brain barrier and cover bacteria in the cerebral spinal fluid, especially ceftriaxone and cefotaxime. Ceftriaxone can be&#x000a0;prescribed&#x000a0;to treat meningitis caused by <italic toggle="yes">H influenzae</italic>,&#x000a0;<italic toggle="yes">Neisseria meningitidis</italic>, or&#x000a0;<italic toggle="yes">Streptococcus pneumoniae. </italic>Ceftriaxone&#x000a0;is also used to treat gonorrhea and disseminated Lyme disease. Ceftazidime, very importantly, has <italic toggle="yes">P</italic><italic toggle="yes">seudomonas</italic>
<italic toggle="yes">aeruginosa </italic>coverage.<xref ref-type="bibr" rid="article-19158.r5">[5]</xref>&#x000a0;</p>
        <p>Fourth-generation cephalosporin includes cefepime. Cefepime is a broad-spectrum antimicrobial that can penetrate the cerebral spinal fluid. Cefepime has an additional quaternary ammonium group, allowing it to better penetrate the outer membrane of gram-negative bacteria. Similar to the activity of cefotaxime and ceftriaxone, cefepime can cover <italic toggle="yes">S pneumoniae</italic> and methicillin-sensitive <italic toggle="yes">Staphylococcus aureus</italic> (MSSA). Similar to ceftazidime, cefepime, very importantly, can cover for <italic toggle="yes">P</italic>&#x000a0;<italic toggle="yes">aeruginosa.&#x000a0;</italic>In addition to the gram-negative bacteria that third-generation covers (<italic toggle="yes">Neisseria </italic>spp<italic toggle="yes">, H influenzae</italic>, and Enterobacteriaceae), cefepime can provide coverage against &#x003b2;-lactamase-producing gram-negative bacilli.&#x000a0;Although effective against gram-positive and gram-negative bacteria, cefepime is reserved for severe systemic infection in patients with multi-resistance organisms.<xref ref-type="bibr" rid="article-19158.r6">[6]</xref></p>
        <p>Fifth-generation cephalosporins include ceftaroline and ceftobiprole. Ceftaroline is also a broad-spectrum antimicrobial and thus can cover susceptible gram-positive and gram-negative organisms. However, what makes it unique from the rest of the cephalosporins is coverage against methicillin-resistant <italic toggle="yes">S aureus</italic>&#x000a0;(MRSA). Ceftaroline can also cover <italic toggle="yes">Listeria</italic>
<italic toggle="yes">monocytogenes</italic> and <italic toggle="yes">Enterococcus faecalis</italic>. However, ceftaroline does not cover <italic toggle="yes">P aeruginosa</italic>.<xref ref-type="bibr" rid="article-19158.r7">[7]</xref>&#x000a0;Ceftobiprole (pending approval from the US Food and Drug Administration, FDA) has activity against MRSA,&#x000a0;<italic toggle="yes">E faecalis</italic>, and penicillin-resistant&#x000a0;<italic toggle="yes">S pneumoniae</italic>.<xref ref-type="bibr" rid="article-19158.r8">[8]</xref><xref ref-type="bibr" rid="article-19158.r9">[9]</xref><xref ref-type="bibr" rid="article-19158.r10">[10]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Cefiderocol is a novel siderophore cephalosporin that exhibits remarkable antibacterial activity.&#x000a0;This drug was approved by the US Food and Drug Administration (FDA) in November 2019 to treat complicated urinary tract infections and ventilator-associated pneumonia caused by highly resistant gram-negative bacteria. The approval is specifically for cases caused by susceptible gram-negative microorganisms, such as <italic toggle="yes">K pneumonia, E coli, P aeruginosa</italic>, <italic toggle="yes">P mirabilis, </italic>and<italic toggle="yes"> Acinetobacter baumannii</italic>.<italic toggle="yes">&#x000a0;</italic></p>
        <p>Cefiderocol demonstrates notable effectiveness against gram-negative bacteria with multidrug resistance, especially those resistant to carbapenems.&#x000a0;Literature review&#x000a0;suggests cefiderocol as a promising therapeutic option for addressing challenging infections caused by strains resistant to carbapenems.<xref ref-type="bibr" rid="article-19158.r11">[11]</xref><xref ref-type="bibr" rid="article-19158.r12">[12]</xref> Importantly, cefiderocol&#x000a0;is the only recently approved&#x000a0;&#x003b2;-lactam agent exhibiting in vitro activity against carbapenem-resistant&#x000a0;<italic toggle="yes">A baumannii</italic>&#x000a0;(CRAB) isolates. According to the Infectious Diseases Society of America guidelines, cefiderocol should be reserved for cases of CRAB infections that remain unresponsive to other antibiotics or when intolerance to alternative agents prohibits their use.<xref ref-type="bibr" rid="article-19158.r13">[13]</xref></p>
      </sec>
      <sec id="article-19158.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Bacteria synthesize a cell wall strengthened by cross-linking peptidoglycan units via penicillin-binding proteins (PBP, peptidoglycan transpeptidase). Initially derived from the fungus <italic toggle="yes">Cephalosporium sp.</italic>, cephalosporins are a large group of bactericidal antimicrobials that work via their &#x003b2;-lactam rings. The &#x003b2;-lactam rings bind to the penicillin-binding protein and inhibit its normal activity. Unable to synthesize a cell wall, the bacteria die.&#x000a0;The inability to synthesize a cell wall eventually leads to bacterial cell death.</p>
        <p><italic toggle="yes">S aureus,</italic>&#x000a0;susceptible to cephalosporins, can develop resistance by changing the structure of the penicillin-binding proteins.&#x000a0;<italic toggle="yes">S aureus</italic>&#x000a0;does this by having a gene that encodes a modified penicillin-binding protein; this prevents the cephalosporin's &#x003b2;-lactam rings from inactivating the protein. The bacterium that develops this resistance mechanism is MRSA. As&#x000a0;mentioned above, out of the five generations of cephalosporin, only the fifth generation of ceftaroline has coverage against MRSA. Another crucial resistance mechanism is producing the enzyme &#x003b2;-lactamase, which cleaves the &#x003b2;-lactam ring, preventing it from attaching to the penicillin-binding proteins, eg, peptidoglycan transpeptidase. &#x003b2;-lactamase inhibitors can be co-formulated with cephalosporins to increase their spectrum of activity, eg, ceftazidime/avibactam and ceftolozane/tazobactam.</p>
        <p>Similar to cefepime and ceftazidime, it features a pyrrolidine group at the C3 position for stability and a carboxy-propanoxyamino group at C7 to aid in outer membrane transport. Iron transporters recognize this, enabling efficient penetration to the periplasm, where it strongly binds to PBP-3. Termed the "Trojan horse," this strategy effectively addresses porin loss resistance. Cefiderocol's structural attributes also ensure stability against &#x003b2;-lactamases, including minor carbapenemases.</p>
        <p>Cefiderocol is a siderophore cephalosporin with a distinctive structure and mechanism that enhances its potent antibacterial properties. Including a chlorocatechol residue sets it apart from its counterparts, categorizing it as a siderophore. This attribute makes it recognizable by iron transporters and facilitates efficient penetration to the periplasm, where it binds strongly to penicillin-binding proteins. This strategy is called the "trojan horse," which effectively addresses porin loss resistance. Cefiderocol's&#x000a0;properties also ensure stability against &#x003b2;-lactamases, including minor carbapenemases.<xref ref-type="bibr" rid="article-19158.r12">[12]</xref><xref ref-type="bibr" rid="article-19158.r14">[14]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Cephalexin, cephradine, cefaclor, cefixime, cefadroxil, cefprozil, cefpodoxime, ceftibuten, cefuroxime demonstrate effective absorption following oral administration.</p>
        <p><bold>Distribution:&#x000a0;</bold>Certain cephalosporins, such as ceftriaxone, cefotaxime, ceftazidime, and cefepime, can effectively penetrate the blood-brain barrier, making them a valuable treatment option for meningitis.<xref ref-type="bibr" rid="article-19158.r15">[15]</xref><xref ref-type="bibr" rid="article-19158.r16">[16]</xref>&#x000a0;Cephalosporins can also cross the placenta and are present in high concentrations in synovial fluid.<xref ref-type="bibr" rid="article-19158.r17">[17]</xref>&#x000a0;After systemic administration of third-generation cephalosporins, they can penetrate well into the aqueous humor. Ceftolozane/tazobactam, ceftobiprole, ceftazidime/avibactam and ceftaroline have excellent&#x000a0;pulmonary penetration.<xref ref-type="bibr" rid="article-19158.r18">[18]</xref></p>
        <p><bold>Metabolism:</bold> Cefotaxime undergoes metabolic conversion to a biologically active compound known as desacetyl-cefotaxime. This metabolite exhibits favorable antibacterial properties, effective penetration into extravascular tissues, and synergy with cefotaxime.&#x000a0;Cefoperazone,&#x000a0;ceftazidime,&#x000a0;and ceftriaxone have significant biliary excretion.<xref ref-type="bibr" rid="article-19158.r19">[19]</xref><xref ref-type="bibr" rid="article-19158.r20">[20]</xref><xref ref-type="bibr" rid="article-19158.r21">[21]</xref></p>
        <p><bold>Excretion:</bold>&#x000a0;Cephalosporins are primarily excreted via renal pathways, necessitating dosage adjustments in cases of renal insufficiency. Exceptions include cefpiramide and cefoperazone, primarily excreted in bile. Ceftriaxone, conversely, exhibits mixed renal/nonrenal elimination.<xref ref-type="bibr" rid="article-19158.r22">[22]</xref>&#x000a0;Like penicillins, probenecid can&#x000a0;reduce the&#x000a0;renal tubular secretion of the cephalosporins.</p>
      </sec>
      <sec id="article-19158.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms, Strengths, and Adult Dosages</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>First-generation: Cefazolin, cephalothin, and cephapirin are administered parenterally. The administration route for cefadroxil and cephalexin is oral. Cephradine administration can be parenteral or oral.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Second-generation: Cefuroxime can be administered parenterally or orally. Cefprozil is administered orally. Cefmetazole, cefotetan, and cefoxitin are administered parenterally.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Third-generation: Cefotaxime, ceftazidime, and ceftriaxone administration via the parenteral route. Cefdinir, cefixime, and cefpodoxime are administered orally. A single intramuscular shot of 125 or 250 mg of ceftriaxone effectively treats uncomplicated gonococcal infection or its complications, such as pelvic inflammatory disease&#x000a0;or epididymo-orchitis.<xref ref-type="bibr" rid="article-19158.r23">[23]</xref><xref ref-type="bibr" rid="article-19158.r24">[24]</xref><xref ref-type="bibr" rid="article-19158.r25">[25]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fourth-generation: Cefepime is administered parenterally.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Fifth-generation: Ceftaroline is administered parenterally.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cefiderocol: Cefiderocol is administered parenterally.<xref ref-type="bibr" rid="article-19158.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment</bold>: Generally, cephalosporins are known for their low propensity for hepatotoxicity, and instances of drug-induced liver injury attributed to these agents are infrequent in the published literature. Notably, an exception exists with ceftriaxone, a third-generation cephalosporin. When administered parenterally, ceftriaxone has been associated with the formation of biliary sludge, with symptoms resembling those of cholecystitis and cholestatic jaundice.<xref ref-type="bibr" rid="article-19158.r26">[26]</xref>&#x000a0;Pharmacokinetic investigations conducted in cirrhosis have&#x000a0;demonstrated heterogeneous results concerning the half-life of cefotaxime. However, cefotaxime has a broad therapeutic index, suggesting that dosage adjustments may not be&#x000a0;necessary&#x000a0;for hepatic impairment. In the context of spontaneous bacterial peritonitis therapy, cefotaxime's comprehensive coverage and high ascitic fluid concentrations make it a preferred antibiotic. Empirical antibiotic therapy, cefotaxime, administered every&#x000a0;8 hours, has demonstrated excellent ascitic fluid concentrations and clinical efficacy.<xref ref-type="bibr" rid="article-19158.r27">[27]</xref></p>
        <p><bold>Renal impairment</bold>: Many parenterally administered cephalosporins have short half-lives and must be given more frequently in patients with normal renal function. Cefazolin and ceftriaxone do not require frequent dosing due to their longer half-life. Ceftriaxone&#x000a0;does not require dose modification in renal failure. However, the recommended daily dosage should not exceed 2 g in renal and hepatic impairment patients.<xref ref-type="bibr" rid="article-19158.r28">[28]</xref>&#x000a0;In&#x000a0;chronic kidney disease&#x000a0;patients, careful dosing of cephalosporins is imperative to mitigate drug accumulation and associated adverse effects. Cefepime, a fourth-generation cephalosporin, necessitates vigilant renal function monitoring and dose adjustment due to its potential neurotoxicity in renal impairment.&#x000a0;Conversely, cephalosporins like cefazolin and ceftazidime, excreted renally, present an opportunity for streamlined dosing in hemodialysis. Administering these agents&#x000a0;3 times weekly post-hemodialysis&#x000a0;optimizes convenience and adherence. Individualized decisions, guided by patient-specific factors and&#x000a0;nephrotoxicity potential&#x000a0;guidelines, are essential to ensure therapeutic efficacy while minimizing risks in chronic kidney disease management.<xref ref-type="bibr" rid="article-19158.r29">[29]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>The guidelines provided by the American College of Obstetricians and Gynecologists (ACOG) for preventing Group B Streptococcal infection recommend the use of first-generation cephalosporins, specifically cefazolin, for women who have a documented penicillin allergy that indicates a lower risk of anaphylaxis or whose allergy severity is uncertain.<xref ref-type="bibr" rid="article-19158.r30">[30]</xref></p>
        <p><bold>Breastfeeding considerations:</bold> Cephalosporin antibiotics, including cefadroxil, cefazolin, cefepime, cefiderocol, cefixime, cefotaxime, cefpodoxime, ceftaroline, and ceftazidime, are generally considered acceptable for use in nursing mothers. These medications produce low&#x000a0;concentrations&#x000a0;in breast milk and are not anticipated to cause adverse effects in breastfed infants.<xref ref-type="bibr" rid="article-19158.r31">[31]</xref><xref ref-type="bibr" rid="article-19158.r32">[32]</xref><xref ref-type="bibr" rid="article-19158.r33">[33]</xref>&#x000a0;Occasional reports mention the potential for disruption of the infant's gastrointestinal flora, leading to diarrhea or thrush; overall, cephalosporins are deemed suitable during breastfeeding.<xref ref-type="bibr" rid="article-19158.r34">[34]</xref><xref ref-type="bibr" rid="article-19158.r35">[35]</xref><xref ref-type="bibr" rid="article-19158.r36">[36]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;In children with acute bacterial arthritis due to MSSA, the preferred initial intravenous treatment is a &#x003b2;-lactam agent like cefazolin. Cephalexin is the recommended choice for subsequent oral treatment. Ceftaroline is a reasonable alternative to clindamycin in acute bacterial arthritis caused by MRSA.<xref ref-type="bibr" rid="article-19158.r37">[37]</xref></p>
        <p><bold>Older patients:</bold> Older patients with renal impairment and central nervous system (CNS) disorders are at risk of neurotoxicity. Cefepime-induced neurotoxicity may present with altered mental status, myoclonus, and seizures.<xref ref-type="bibr" rid="article-19158.r38">[38]</xref></p>
      </sec>
      <sec id="article-19158.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Cephalosporins have low toxicity and are generally safe. The most common adverse reactions from cephalosporins are nausea, vomiting, lack of appetite, and abdominal pain. Important adverse drug reactions are enumerated below.</p>
        <p><bold>Hypersensitivity reactions:</bold>&#x000a0;A hypersensitivity reaction to cephalosporin is infrequent and is more common in first and second-generation cephalosporins. Common allergic reactions to cephalosporin include rash, hives, and swelling. The hypersensitivity reaction will rarely result in anaphylaxis. Patients allergic to penicillin might also show a hypersensitive reaction to cephalosporins. This cross-reactivity is more common in first and second-generation cephalosporins because they have R-groups more similar to penicillin G. Third-generation and beyond show minimal cross-reactivity.<xref ref-type="bibr" rid="article-19158.r39">[39]</xref><xref ref-type="bibr" rid="article-19158.r40">[40]</xref></p>
        <p><bold>Drug-induced immune hemolytic anemia:</bold>&#x000a0;The proposed mechanism of action of&#x000a0;drug-induced immune hemolytic anemia (DIIHA) is that the drug binds to the red blood cell membrane; this causes no harm to the red blood cell itself or the patient. However, if the patient starts making IgG antibodies against the drug, the antibody will bind to the red blood cell. The immune system will react with the abnormal red blood cells, resulting in hemolysis. Cefotetan and ceftriaxone are the&#x000a0;2 cephalosporins most likely to cause DIIHA.<xref ref-type="bibr" rid="article-19158.r41">[41]</xref>&#x000a0;</p>
        <p><bold>Disulfiram-like reactions:</bold>&#x000a0;Cephalosporins containing a methyl-tetrazole-thiol side chain can inhibit the aldehyde dehydrogenase enzyme, resulting in the accumulation of acetaldehyde. Cefamandole, cefoperazone, and moxalactam are the most common cephalosporins to present with this reaction.<xref ref-type="bibr" rid="article-19158.r42">[42]</xref></p>
        <p><bold>Vitamin K deficiency:</bold>&#x000a0;Certain cephalosporins can inhibit vitamin K epoxide reductase, preventing the production of the reduced (active) vitamin K. Therefore, a decreased synthesis of coagulation factors may occur, and the patient is predisposed to hypoprothrombinemia.<xref ref-type="bibr" rid="article-19158.r43">[43]</xref>&#x000a0;</p>
        <p>Pseudomembranous colitis:&#x000a0;Pseudomembranous colitis is often associated with clindamycin and ampicillin. Cephalosporin use is also a common cause of pseudomembranous colitis, especially third-generation cephalosporins.<xref ref-type="bibr" rid="article-19158.r44">[44]</xref><xref ref-type="bibr" rid="article-19158.r45">[45]</xref>&#x000a0;</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>Warfarin:</bold> Cephalosporins containing an <italic toggle="yes">N</italic>-methyl-thiotetrazole (NMTT) side chain are predominantly found in cefotetan, cefamandole, cefmetazole, cefoperazone, moxalactam. NMTT-cephalosporins induce hemostatic abnormalities, such as bleeding, prothrombin time prolongation, and hypoprothrombinemia, due to the NMTT's chemical structure interfering with vitamin K metabolism.&#x000a0;These cephalosporins can interact with warfarin, potentiating the risk of hypoprothrombinemia and increasing the likelihood of bleeding incidents.<xref ref-type="bibr" rid="article-19158.r46">[46]</xref>&#x000a0;Additionally, the literature review suggests that ceftaroline poses a risk of interaction with warfarin, potentially leading to elevated INR levels and an increased bleeding risk. Saum et al focused on ceftriaxone and discovered significant increases in INR values compared to other antibiotics. This suggests caution when using cephalosporins in patients on chronic warfarin therapy.<xref ref-type="bibr" rid="article-19158.r47">[47]</xref><xref ref-type="bibr" rid="article-19158.r48">[48]</xref></p>
        <p><bold>Furosemide:</bold> Concurrent use of cephalosporins and furosemide can&#x000a0;increase the risk of&#x000a0;nephrotoxicity.<xref ref-type="bibr" rid="article-19158.r49">[49]</xref><xref ref-type="bibr" rid="article-19158.r50">[50]</xref></p>
        <p><bold>Aminoglycosides:</bold> Reported cases of drug-induced nephrotoxicity consist of cephalosporin and aminoglycosides in combination, but other factors often cloud the evidence. Therefore, the synergistic nephrotoxicity of cephalosporin and aminoglycoside is not completely understood.<xref ref-type="bibr" rid="article-19158.r45">[45]</xref><xref ref-type="bibr" rid="article-19158.r51">[51]</xref>&#x000a0;Concurrent use of cefepime with other aminoglycoside antibiotics increases the risk of nephrotoxicity.<xref ref-type="bibr" rid="article-19158.r52">[52]</xref><xref ref-type="bibr" rid="article-19158.r53">[53]</xref></p>
      </sec>
      <sec id="article-19158.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>One of the contraindications of cephalosporins is if patients are allergic to them or have had an anaphylactic reaction to penicillin or other &#x003b2;-lactam antimicrobials. The cross-reactivity is thought to be due to similar side chains, not the &#x003b2;-lactam ring. However, it is important to understand the contraindications according to the latest guidelines. The guidelines provided by the American Academy of Allergy, Asthma &#x00026; Immunology (AAAAI) and the American College of Allergy, Asthma, and Immunology (ACAAI) offer recommendations for managing patients with a history of cephalosporin or penicillin allergies.<xref ref-type="bibr" rid="article-19158.r54">[54]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>In instances where patients have a history of nonanaphylactic allergy to cephalosporins, the guidelines from AAAAI and ACAAI suggest the performance of direct challenges to cephalosporins with dissimilar side chains. The guidelines do not advocate for skin tests before the direct challenge.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The guidelines recommend confirming a negative cephalosporin skin test for patients with a history of anaphylaxis to a cephalosporin before administering a parenteral cephalosporin with a nonidentical R1 side chain.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In cases where patients have a history of anaphylaxis to penicillin, the guidelines suggest administering a structurally dissimilar R1 side chain cephalosporin without necessitating testing or additional precautions. If any uncertainty exists about allergy testing, it is recommended to consult with an immunologist. A detailed explanation is provided in the guidelines.&#x000a0;</p>
          </list-item>
        </list>
        <p>Ceftriaxone is contraindicated in neonates with hyperbilirubinemia because of reports that ceftriaxone displaces bilirubin from albumin, increasing the free bilirubin concentrations and increasing the risk of jaundice in neonates.<xref ref-type="bibr" rid="article-19158.r55">[55]</xref><xref ref-type="bibr" rid="article-19158.r56">[56]</xref>&#x000a0;Ceftriaxone reacts to a calcium-containing solution, and ceftriaxone-calcium crystals can precipitate in the lungs and kidneys of infants less than 28 days old, which could be life-threatening. Therefore, ceftriaxone is also contraindicated in infants under 28 days old if they are expected to receive calcium-containing products.<xref ref-type="bibr" rid="article-19158.r57">[57]</xref></p>
      </sec>
      <sec id="article-19158.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring for possible signs of anaphylaxis and allergic reactions such as hives, itching, and swelling is essential.&#x000a0;Clinicians and pharmacists&#x000a0;should also&#x000a0;monitor renal function periodically, which could potentially warrant changing the cephalosporin dose and dosing frequency (except for ceftriaxone).<xref ref-type="bibr" rid="article-19158.r58">[58]</xref>&#x000a0;If&#x000a0;DIIHA is suspected, monitor complete blood count (CBC), bilirubin, haptoglobin, and LDH.<xref ref-type="bibr" rid="article-19158.r59">[59]</xref>&#x000a0;Clinicians should also monitor for possible signs of a disulfiram-like reaction or pseudomembranous colitis.<xref ref-type="bibr" rid="article-19158.r60">[60]</xref><xref ref-type="bibr" rid="article-19158.r61">[61]</xref>&#x000a0;Monitor PT/INR for concerns regarding hypoprothrombinemia.<xref ref-type="bibr" rid="article-19158.r62">[62]</xref><xref ref-type="bibr" rid="article-19158.r63">[63]</xref></p>
      </sec>
      <sec id="article-19158.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>After conducting experiments on rabbits to test the effects of high-dosage cephalosporin, it has been discovered that the drug's impact on the mitochondria system of the kidney results in nephrotoxicity.<xref ref-type="bibr" rid="article-19158.r64">[64]</xref>&#x000a0;Cefepime overdose can result in seizures and encephalopathy. Studies show it to potentially&#x000a0;result from cefepime crossing the blood-brain barrier and displaying concentration-dependent &#x003d2;-aminobutyric acid (GABA) antagonism, which can also occur with toxic doses of penicillin G. Other studies show altered mental status and a triphasic wave discharge on electroencephalogram (EEG). Discontinuation of cefepime demonstrates normalization of mental status.<xref ref-type="bibr" rid="article-19158.r65">[65]</xref><xref ref-type="bibr" rid="article-19158.r66">[66]</xref>&#x000a0;</p>
        <p>A study analyzed 511 severe adverse drug reaction reports on cephalosporins recorded in the French Pharmacovigilance database from 1987 to 2017. Patients, primarily older men with compromised renal function, experienced various CNS manifestations, including encephalopathy, confusional state, convulsions, and myoclonia. Cefepime and ceftriaxone were the most implicated cephalosporins.<xref ref-type="bibr" rid="article-19158.r67">[67]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Management of neurotoxicity and seizures involves discontinuing the offending cephalosporin, providing supportive care, and initiating anticonvulsant therapy if necessary.<xref ref-type="bibr" rid="article-19158.r68">[68]</xref></p>
      </sec>
      <sec id="article-19158.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effective teamwork among healthcare professionals is vital for providing quality patient care. A shared goal, clear roles, and trust between the team members can increase efficiency. Clinicians should accurately diagnose, prescribe, and inform patients of adverse effects. Nurses should be aware of potential adverse drug reactions. Pharmacists can educate patients, provide information on adverse effects, and report potential interactions to clinicians. A recent study showed that pharmacist-led antimicrobial stewardship interventions, specifically focusing on antibiotics, led to lasting improvements such as increased blood culture collections, more frequent de-escalation of agents, and a significant reduction in hospital-acquired infections.<xref ref-type="bibr" rid="article-19158.r69">[69]</xref>&#x000a0;</p>
        <p>Patients&#x000a0;should be&#x000a0;advised to promptly communicate any&#x000a0;unusual&#x000a0;symptoms they may be experiencing to both the clinician and nurse. Through effective interprofessional teamwork, appropriate management of cephalosporin adverse drug reactions can occur, resulting in better patient outcomes.&#x000a0;Adopting an interprofessional team-based approach that involves clinicians, infectious disease specialists, pharmacists, and patients is instrumental in achieving the desired therapeutic outcomes of&#x000a0;cephalosporins.</p>
      </sec>
      <sec id="article-19158.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19158&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19158">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19158/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19158">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19158.s11">
        <title>References</title>
        <ref id="article-19158.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsieh</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of antibacterial activities of cephalosporin antibiotics: cefazolin, cephaloridine, cephalothin, and cephalexin.</article-title>
            <source>Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi</source>
            <year>1975</year>
            <month>Mar</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">1097210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffith</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>The pharmacology of cephalexin.</article-title>
            <source>Postgrad Med J</source>
            <year>1983</year>
            <volume>59 Suppl 5</volume>
            <fpage>16</fpage>
            <page-range>16-27</page-range>
            <pub-id pub-id-type="pmid">6364086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bergeron</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Brusch</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Barza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Bactericidal activity and pharmacology of cefazolin.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1973</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>396</fpage>
            <page-range>396-401</page-range>
            <pub-id pub-id-type="pmid">4598612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tartaglione</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Polk</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime.</article-title>
            <source>Drug Intell Clin Pharm</source>
            <year>1985</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>188</fpage>
            <page-range>188-98</page-range>
            <pub-id pub-id-type="pmid">3884304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Cunha</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Third-generation cephalosporins.</article-title>
            <source>Med Clin North Am</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>705</fpage>
            <page-range>705-19</page-range>
            <pub-id pub-id-type="pmid">7791418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okamoto</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Nakahiro</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bedikian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Cefepime: a new fourth-generation cephalosporin.</article-title>
            <source>Am J Hosp Pharm</source>
            <year>1994</year>
            <month>Feb</month>
            <day>15</day>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>463</fpage>
            <page-range>463-77; quiz 541-2</page-range>
            <pub-id pub-id-type="pmid">8017411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhanel</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Sniezek</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schweizer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zelenitsky</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lagac&#x000e9;-Wiens</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Rubinstein</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gin</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hoban</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Karlowsky</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.</article-title>
            <source>Drugs</source>
            <year>2009</year>
            <volume>69</volume>
            <issue>7</issue>
            <fpage>809</fpage>
            <page-range>809-31</page-range>
            <pub-id pub-id-type="pmid">19441869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahmoud</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Al Mansour</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bosaeed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alharbi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alsaedy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aljohani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alalwan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Alothman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ceftobiprole for Treatment of MRSA Blood Stream Infection: A Case Series.</article-title>
            <source>Infect Drug Resist</source>
            <year>2020</year>
            <volume>13</volume>
            <fpage>2667</fpage>
            <page-range>2667-2672</page-range>
            <pub-id pub-id-type="pmid">32821130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsu</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Ceftobiprole medocaril for the treatment of pneumonia.</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>551</fpage>
            <page-range>551-563</page-range>
            <pub-id pub-id-type="pmid">37042813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lupia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pallotto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Corcione</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boglione</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>De Rosa</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>Ceftobiprole Perspective: Current and Potential Future Indications.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2021</year>
            <month>Feb</month>
            <day>08</day>
            <volume>10</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">33567771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.</article-title>
            <source>Front Pharmacol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>896971</fpage>
            <pub-id pub-id-type="pmid">35496290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Domingues</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saavedra</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Da Silva</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms.</article-title>
            <source>Life (Basel)</source>
            <year>2023</year>
            <month>Jun</month>
            <day>21</day>
            <volume>13</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">37511802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Aitken</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mathers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van Duin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Infectious Diseases Society of America Guidance on the Treatment of AmpC &#x003b2;-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.</article-title>
            <source>Clin Infect Dis</source>
            <year>2022</year>
            <month>Jul</month>
            <day>06</day>
            <volume>74</volume>
            <issue>12</issue>
            <fpage>2089</fpage>
            <page-range>2089-2114</page-range>
            <pub-id pub-id-type="pmid">34864936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nishikawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yoshizawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tsuji</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamano</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>60</volume>
            <issue>12</issue>
            <fpage>7396</fpage>
            <page-range>7396-7401</page-range>
            <pub-id pub-id-type="pmid">27736756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rhoney</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Tam</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McKinnon</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Coplin</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Disposition of cefepime in the central nervous system of patients with external ventricular drains.</article-title>
            <source>Pharmacotherapy</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>310</fpage>
            <page-range>310-4</page-range>
            <pub-id pub-id-type="pmid">12627928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>S&#x000f6;rgel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eiffert</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2010</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>858</fpage>
            <page-range>858-83</page-range>
            <pub-id pub-id-type="pmid">20930076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thabit</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Fatani</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Bamakhrama</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Barnawi</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Basudan</surname>
                <given-names>LO</given-names>
              </name>
              <name>
                <surname>Alhejaili</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic penetration into bone and joints: An updated review.</article-title>
            <source>Int J Infect Dis</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>81</volume>
            <fpage>128</fpage>
            <page-range>128-136</page-range>
            <pub-id pub-id-type="pmid">30772469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lupia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Corcione</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mornese Pinna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Rosa</surname>
                <given-names>FG</given-names>
              </name>
            </person-group>
            <article-title>New cephalosporins for the treatment of pneumonia in internal medicine wards.</article-title>
            <source>J Thorac Dis</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>3747</fpage>
            <page-range>3747-3763</page-range>
            <pub-id pub-id-type="pmid">32802454</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>The effect of obstruction on the biliary excretion of cefoperazone and ceftazidime.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>1990</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>399</fpage>
            <page-range>399-406</page-range>
            <pub-id pub-id-type="pmid">2187012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramchandani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic management of acute cholangitis as a result of common bile duct stones.</article-title>
            <source>Dig Endosc</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>29 Suppl 2</volume>
            <fpage>78</fpage>
            <page-range>78-87</page-range>
            <pub-id pub-id-type="pmid">28425658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ustyol</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bulut</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Agengin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bala</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Yavuz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bora</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Demiroren</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dogan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Comparative evaluation of ceftriaxone- and cefotaxime-induced biliary pseudolithiasis or nephrolithiasis: A prospective study in 154 children.</article-title>
            <source>Hum Exp Toxicol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>547</fpage>
            <page-range>547-553</page-range>
            <pub-id pub-id-type="pmid">27402682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alasmari</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Alasmari</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Muwainea</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Alomar</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Alasmari</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Alsanea</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alshamsan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rasool</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Alqahtani</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing.</article-title>
            <source>Front Pharmacol</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1200828</fpage>
            <pub-id pub-id-type="pmid">37547336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Judson</surname>
                <given-names>FN</given-names>
              </name>
            </person-group>
            <article-title>Treatment of uncomplicated gonorrhea with ceftriaxone: a review.</article-title>
            <source>Sex Transm Dis</source>
            <year>1986</year>
            <season>Jul-Sep</season>
            <volume>13</volume>
            <issue>3 Suppl</issue>
            <fpage>199</fpage>
            <page-range>199-202</page-range>
            <pub-id pub-id-type="pmid">3094173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jennings</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Krywko</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <chapter-title>Pelvic Inflammatory Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">29763134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rupp</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <chapter-title>Epididymitis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">28613565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r26">
          <label>26</label>
          <element-citation publication-type="book">
            <chapter-title>Cephalosporins</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>12</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">31643977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zoratti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moretti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rebuzzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Albergati</surname>
                <given-names>IV</given-names>
              </name>
              <name>
                <surname>Di Somma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Decorti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Bella</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Croc&#x000e8;</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Giuffr&#x000e8;</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Antibiotics and Liver Cirrhosis: What the Physicians Need to Know.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2021</year>
            <month>Dec</month>
            <day>28</day>
            <volume>11</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">35052907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andriole</surname>
                <given-names>VT</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of cephalosporins in patients with normal or reduced renal function.</article-title>
            <source>J Infect Dis</source>
            <year>1978</year>
            <month>May</month>
            <volume>137 Suppl</volume>
            <fpage>S88</fpage>
            <page-range>S88-S99</page-range>
            <pub-id pub-id-type="pmid">349098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vondracek</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Teitelbaum</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kiser</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Principles of Kidney Pharmacotherapy for the Nephrologist: Core Curriculum 2021.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>442</fpage>
            <page-range>442-458</page-range>
            <pub-id pub-id-type="pmid">34275659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <article-title>Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion Summary, Number 782.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>134</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <pub-id pub-id-type="pmid">31241596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <chapter-title>Cefadroxil</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>1</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000351</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <chapter-title>Cefazolin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>10</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30000362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <chapter-title>Cefepime</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>4</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r34">
          <label>34</label>
          <element-citation publication-type="book">
            <chapter-title>Cefpodoxime</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>1</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r35">
          <label>35</label>
          <element-citation publication-type="book">
            <chapter-title>Ceftaroline</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>7</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30000789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r36">
          <label>36</label>
          <element-citation publication-type="book">
            <chapter-title>Ceftazidime</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>10</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30000480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woods</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kronman</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Copley</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Arrieta</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eppes</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Creech</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Stadler</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Mazur</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Carrillo-Marquez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline by the Pediatric Infectious Diseases Society (PIDS) and the Infectious Diseases Society of America (IDSA): 2023 Guideline on Diagnosis and Management of Acute Bacterial Arthritis in Pediatrics.</article-title>
            <source>J Pediatric Infect Dis Soc</source>
            <year>2024</year>
            <month>Jan</month>
            <day>29</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-59</page-range>
            <pub-id pub-id-type="pmid">37941444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grill</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Maganti</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring.</article-title>
            <source>Ann Pharmacother</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>12</issue>
            <fpage>1843</fpage>
            <page-range>1843-50</page-range>
            <pub-id pub-id-type="pmid">19033476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moreno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mac&#x000ed;as</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>D&#x000e1;vila</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Laffond</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lorente</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Hypersensitivity reactions to cephalosporins.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2008</year>
            <month>May</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>295</fpage>
            <page-range>295-304</page-range>
            <pub-id pub-id-type="pmid">18462187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dickson</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Salazar</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of immediate hypersensitivity reactions to cephalosporins.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>131</fpage>
            <page-range>131-42</page-range>
            <pub-id pub-id-type="pmid">23546989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garratty</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced immune hemolytic anemia.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2009</year>
            <fpage>73</fpage>
            <page-range>73-9</page-range>
            <pub-id pub-id-type="pmid">20008184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uri</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Parks</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Disulfiram-like reaction to certain cephalosporins.</article-title>
            <source>Ther Drug Monit</source>
            <year>1983</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>219</fpage>
            <page-range>219-24</page-range>
            <pub-id pub-id-type="pmid">6224316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shearer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bechtold</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Andrassy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Koderisch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Trenk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>J&#x000e4;hnchen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ritz</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1988</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <page-range>88-95</page-range>
            <pub-id pub-id-type="pmid">3350995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Lalla</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Privitera</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ortisi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rizzardini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pagano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rinaldi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Scarpellini</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Third generation cephalosporins as a risk factor for Clostridium difficile-associated disease: a four-year survey in a general hospital.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>1989</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>623</fpage>
            <page-range>623-31</page-range>
            <pub-id pub-id-type="pmid">2663814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rankin</surname>
                <given-names>GO</given-names>
              </name>
              <name>
                <surname>Sutherland</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Nephrotoxicity of aminoglycosides and cephalosporins in combination.</article-title>
            <source>Adverse Drug React Acute Poisoning Rev</source>
            <year>1989</year>
            <season>Summer</season>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>73</fpage>
            <page-range>73-88</page-range>
            <pub-id pub-id-type="pmid">2672726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The Association Between Cephalosporin and Hypoprothrombinemia: A Systematic Review and Meta-Analysis.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2019</year>
            <month>Oct</month>
            <day>16</day>
            <volume>16</volume>
            <issue>20</issue>
            <pub-id pub-id-type="pmid">31623191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baillargeon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Raji</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>YF</given-names>
              </name>
            </person-group>
            <article-title>Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults.</article-title>
            <source>Am J Med</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>125</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-9</page-range>
            <pub-id pub-id-type="pmid">22269622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vega</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Matejowsky</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Thornhill</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Borne</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Mosieri</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Shekoohi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cornett</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Warfarin and Antibiotics: Drug Interactions and Clinical Considerations.</article-title>
            <source>Life (Basel)</source>
            <year>2023</year>
            <month>Jul</month>
            <day>30</day>
            <volume>13</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">37629518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maideen</surname>
                <given-names>NMP</given-names>
              </name>
              <name>
                <surname>Balasubramanian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Muthusamy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A Comprehensive Review of the Pharmacologic Perspective on Loop Diuretic Drug Interactions with Therapeutically Used Drugs.</article-title>
            <source>Curr Drug Metab</source>
            <year>2022</year>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>188</fpage>
            <page-range>188-199</page-range>
            <pub-id pub-id-type="pmid">35366769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pea</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Furlanut</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2001</year>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>833</fpage>
            <page-range>833-68</page-range>
            <pub-id pub-id-type="pmid">11735605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silverblatt</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of nephrotoxicity of cephalosporins and aminoglycosides: a review of current concepts.</article-title>
            <source>Rev Infect Dis</source>
            <year>1982</year>
            <season>Sep-Oct</season>
            <volume>4 Suppl</volume>
            <fpage>S360</fpage>
            <page-range>S360-5</page-range>
            <pub-id pub-id-type="pmid">7178755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Matsumura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Teratani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshimoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mineno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nagahama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuwata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The application of an institutional clinical data warehouse to the assessment of adverse drug reactions (ADRs). Evaluation of aminoglycoside and cephalosporin associated nephrotoxicity.</article-title>
            <source>Methods Inf Med</source>
            <year>2007</year>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>516</fpage>
            <page-range>516-22</page-range>
            <pub-id pub-id-type="pmid">17938772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krcm&#x000e9;ry</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fuchsberger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Goc&#x000e1;r</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sal&#x000e1;t</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bodn&#x000e1;rov&#x000e1;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sobota</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Koza</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Svec</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Nephrotoxicity of aminoglycosides, polypeptides and cephalosporins in cancer patients.</article-title>
            <source>Chemotherapy</source>
            <year>1991</year>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>287</fpage>
            <page-range>287-91</page-range>
            <pub-id pub-id-type="pmid">1790727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Solensky</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>DBK</given-names>
              </name>
              <name>
                <surname>Greenhawt</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Horner</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Ledford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rank</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Shaker</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Stukus</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <collab>Chief Editor(s):</collab>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>DBK</given-names>
              </name>
              <name>
                <surname>Shaker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stukus</surname>
                <given-names>DR</given-names>
              </name>
              <collab>Workgroup Contributors:</collab>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Solensky</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>AA</given-names>
              </name>
              <collab>Joint Task Force on Practice Parameters Reviewers:</collab>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>DBK</given-names>
              </name>
              <name>
                <surname>Greenhawt</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Horner</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Ledford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rank</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Shaker</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Stukus</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Drug allergy: A&#x000a0;2022 practice parameter update.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>150</volume>
            <issue>6</issue>
            <fpage>1333</fpage>
            <page-range>1333-1393</page-range>
            <pub-id pub-id-type="pmid">36122788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gulian</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gonard</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dalmasso</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Palix</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Bilirubin displacement by ceftriaxone in neonates: evaluation by determination of 'free' bilirubin and erythrocyte-bound bilirubin.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>1987</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>823</fpage>
            <page-range>823-9</page-range>
            <pub-id pub-id-type="pmid">3610909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bickford</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature.</article-title>
            <source>Pharmacotherapy</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>10</issue>
            <fpage>1389</fpage>
            <page-range>1389-95</page-range>
            <pub-id pub-id-type="pmid">16185184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bradley</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Wassel</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nambiar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events.</article-title>
            <source>Pediatrics</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>123</volume>
            <issue>4</issue>
            <fpage>e609</fpage>
            <page-range>e609-13</page-range>
            <pub-id pub-id-type="pmid">19289450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Sande</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bolton</surname>
                <given-names>WK</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of cefaclor and cephalexin: dosage nomograms for impaired renal function.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1978</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>172</fpage>
            <page-range>172-7</page-range>
            <pub-id pub-id-type="pmid">697345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barcellini</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fattizzo</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Novel pharmacotherapy for drug-induced immune hemolytic anemia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2023</year>
            <season>Sep-Dec</season>
            <volume>24</volume>
            <issue>18</issue>
            <fpage>1927</fpage>
            <page-range>1927-1931</page-range>
            <pub-id pub-id-type="pmid">38037866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farooq</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Urrunaga</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>von Rosenvinge</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Pseudomembranous colitis.</article-title>
            <source>Dis Mon</source>
            <year>2015</year>
            <month>May</month>
            <volume>61</volume>
            <issue>5</issue>
            <fpage>181</fpage>
            <page-range>181-206</page-range>
            <pub-id pub-id-type="pmid">25769243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ren</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jiao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Cephalosporin induced disulfiram-like reaction: a retrospective review of 78 cases.</article-title>
            <source>Int Surg</source>
            <year>2014</year>
            <season>Mar-Apr</season>
            <volume>99</volume>
            <issue>2</issue>
            <fpage>142</fpage>
            <page-range>142-6</page-range>
            <pub-id pub-id-type="pmid">24670024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haba</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Akizuki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hashiguchi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Naito</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Hypoprothrombinemia During Cefmetazole Treatment: A Case Report.</article-title>
            <source>Am J Case Rep</source>
            <year>2022</year>
            <month>Jul</month>
            <day>27</day>
            <volume>23</volume>
            <fpage>e936712</fpage>
            <pub-id pub-id-type="pmid">35891595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Hsiao</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Tsay</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>7</issue>
            <fpage>e0158407</fpage>
            <pub-id pub-id-type="pmid">27463687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tune</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Fravert</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Cephalosporin nephrotoxicity. Transport, cytotoxicity and mitochondrial toxicity of cephaloglycin.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1980</year>
            <month>Oct</month>
            <volume>215</volume>
            <issue>1</issue>
            <fpage>186</fpage>
            <page-range>186-90</page-range>
            <pub-id pub-id-type="pmid">7452482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Payne</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Gagnon</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Riker</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Seder</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Glisic</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Cefepime-induced neurotoxicity: a systematic review.</article-title>
            <source>Crit Care</source>
            <year>2017</year>
            <month>Nov</month>
            <day>14</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>276</fpage>
            <pub-id pub-id-type="pmid">29137682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tchapyjnikov</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Luedke</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Cefepime-Induced Encephalopathy and Nonconvulsive Status Epilepticus: Dispelling an Artificial Dichotomy.</article-title>
            <source>Neurohospitalist</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>100</fpage>
            <page-range>100-104</page-range>
            <pub-id pub-id-type="pmid">30915188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lacroix</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kheloufi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Montastruc</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bennis</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pizzoglio</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Micallef</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database.</article-title>
            <source>J Neurol Sci</source>
            <year>2019</year>
            <month>Mar</month>
            <day>15</day>
            <volume>398</volume>
            <fpage>196</fpage>
            <page-range>196-201</page-range>
            <pub-id pub-id-type="pmid">30683462</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bora</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Demir</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Uzun</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Nonconvulsive status epilepticus cases arising in connection with cephalosporins.</article-title>
            <source>Epilepsy Behav Case Rep</source>
            <year>2016</year>
            <volume>6</volume>
            <fpage>23</fpage>
            <page-range>23-7</page-range>
            <pub-id pub-id-type="pmid">27408805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19158.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ebisawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sakon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kusuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Izuta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yahata</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yano</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Miyara</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Sustained Improvements in Antimicrobial Therapy and Clinical Outcomes following a Pharmacist-Led Antimicrobial Stewardship Intervention: Uncontrolled Before-After Study.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Jan</month>
            <day>23</day>
            <volume>11</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">35160018</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
